This guide is not available in FR yet. Showing the EN version.
Tyrosine kinase inhibitors, also known as TKIs, have been the first-line standard of care for advanced or metastatic renal cell carcinoma for over a decade. Join our 'TKIs for Renal Cell Carcinoma' Patient Education series, in which we explore what they are, how they work, and how to maintain quality of life during TKI treatment.
Custom, evidence-based visual guides in 20+ languages, delivered through structured patient pathways — with zero IT disruption.
Book a Demo
